Dupilumab Effective in Treating Severe Asthma with Small Airway Dysfunction

A real-life study uncovered the positive effects of the drug Dupilumab on severe asthma patients, marking a significant advancement in asthma treatment. Dupilumab, a humanized immunoglobulin G (IgG)–4 monoclonal antibody, has demonstrated remarkable potential in improving asthma-related health parameters.

This innovative research delved into the impact of Dupilumab therapy on patients with uncontrolled severe asthma, specifically selected based on oscillometry-defined Small Airway Dysfunction (SAD). SAD, closely associated with type 2 inflammation and asthma control, was diagnosed when patients exhibited values of R5-R20 greater than or equal to 0.10 kPa/L/s and AX greater than or equal to 1.0 kPa/L at baseline.

The results of the study were astonishing. After only 4.5 months of Dupilumab therapy, significant improvements were observed in oscillometry outcomes. Median improvements in R5-R20 and AX exceeded previously established biologic variability values, indicating a clinically relevant treatment effect. Furthermore, the mean improvements in lung function (FEV1, FEF25-75, and FVC) were substantial, surpassing established biologic variability values for clinical relevance. These improvements were accompanied by significant enhancements in asthma control scores, more than threefold beyond the traditionally accepted minimal clinically important difference.